(Circulation. 1996;94:1233-1238.)
© 1996 American Heart Association, Inc.
Articles |
One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial
Duke University Medical Center, Durham, NC (R.M.C., K.L.L.); Green Lane Hospital, Auckland, New Zealand (H.D.W.); Institut Kardiologu, Warszawa, Poland (Z.S.); University of Alberta, Edmonton, Canada (P.W.A.); Hospital Tenon, Paris, France (A.V.); Thoraxcenter, Erasmus University, Rotterdam, the Netherlands (M.L.S.); National Health Medical Research Council Clinical Trials Centre, University of Sydney, Australia (R.J.S.); University Hospital Gasthuisberg, Leuven, Belgium (F. Van de W.); and the Cleveland (Ohio) Clinic Foundation (E.J.T.).
Correspondence to Robert M. Califf, MD, Box 31123, Duke University Medical Center, Durham, NC 27710.
Background In the randomized Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries (GUSTO-I) trial, 41 021 patients received one of four thrombolytic regimens. Patients treated with accelerated tissue plasminogen activator (TPA) had a lower 30-day mortality rate (6.3%) than those treated with the other regimens (7.3%, combined streptokinase groups).
Methods and Results Each patient who was alive at 30 days was sent a return postcard to ascertain vital status at 1 year. If the postcard was not returned, the patient (or an alternate specified at randomization) was contacted by telephone. A locator service was used in the United States for patients who could not be located by these methods. Final follow-up was 96% worldwide. One-year mortality rates remained in favor of accelerated TPA (9.1%) over streptokinase with subcutaneous heparin (10.1%, P=.011) and streptokinase with intravenous heparin (10.1%, P=.009). Combination therapy had an intermediate 1-year mortality (9.9%); this outcome was statistically indistinguishable from that with streptokinase (P=.47) but was marginally different from that with accelerated TPA (P=.05).
Conclusions The 1-year results demonstrated a saving of 10 lives per 1000 patients treated with accelerated TPA versus streptokinase and subcutaneous or intravenous heparin. Combination thrombolytic therapy had an intermediate benefit but offered no advantage over accelerated TPA treatment alone.
Key Words: mortality • myocardial infarction • follow-up studies • thrombolysis
This article has been cited by other articles:
 |
|
 |
|
  S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Callans Can Home AEDs Improve Survival? N. Engl. J. Med., April 24, 2008; 358(17): 1853 - 1855. [Full Text] [PDF]
|
|
|
|
|
|
G. H. Bardy, K. L. Lee, D. B. Mark, J. E. Poole, W. D. Toff, A. M. Tonkin, W. Smith, P. Dorian, D. L. Packer, R. D. White, et al. Home Use of Automated External Defibrillators for Sudden Cardiac Arrest N. Engl. J. Med., April 24, 2008; 358(17): 1793 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kaul, P. W. Armstrong, W.-C. Chang, C. D. Naylor, C. B. Granger, K. L. Lee, E. D. Peterson, R. M. Califf, E. J. Topol, and D. B. Mark Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada: Comparison of Patients Enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Circulation, September 28, 2004; 110(13): 1754 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Sugeng, L Weinert, and R M Lang Left ventricular assessment using real time three dimensional echocardiography Heart, November 1, 2003; 89(90003): iii29 - 36. [Full Text] [PDF]
|
|
|
|
|
|
J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M. Ohman, S. James, E. Topol, L. Wallentin, M.L. Simoons, et al. Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial Circulation, January 28, 2003; 107(3): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L F Hsu, K H Mak, K W Lau, L L Sim, C Chan, T H Koh, S C Chuah, R Kam, Z P Ding, W S Teo, et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis Heart, September 1, 2002; 88(3): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hudson, C. B. Granger, E. J. Topol, K. S. Pieper, P. W. Armstrong, G. I. Barbash, A. D. Guerci, A. Vahanian, R. M. Califf, and E. M. Ohman Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials Circulation, September 11, 2001; 104(11): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Intravenous NPA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction Eur. Heart J., December 2, 2000; 21(24): 2005 - 2013. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Topol, E. M. Ohman, P. W. Armstrong, R. Wilcox, A. M. Skene, P. Aylward, J. Simes, A. Dalby, A. Betriu, C. Bode, et al. Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction : Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial Circulation, October 10, 2000; 102(15): 1761 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Chareonthaitawee, R J Gibbons, R S Roberts, T F Christian, and R Burns The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction Heart, August 1, 2000; 84(2): 142 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Califf, K. S. Pieper, K. L. Lee, F. Van de Werf, R. J. Simes, P. W. Armstrong, and E. J. Topol Prediction of 1-Year Survival After Thrombolysis for Acute Myocardial Infarction in the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial Circulation, May 16, 2000; 101(19): 2231 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brophy, L. Joseph, and P. Theroux Medical Decision Making in the Choice of a Thrombolytic Agent for Acute Myocardial Infarction Med Decis Making, October 1, 1999; 19(4): 411 - 418. [PDF]
|
|
|
|
 |
|
 J. M. Waugh, M. Kattash, J. Li, E. Yuksel, M. D. Kuo, M. Lussier, A. B. Weinfeld, R. Saxena, E. D. Rabinovsky, S. Thung, et al. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model PNAS, February 2, 1999; 96(3): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Waldecker, W. Waas, W. Haberbosch, R. Voss, H. Heizmann, and H. Tillmanns Long-term follow-up after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1320 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ross, K. S. Coyne, E. Moreyra, J. S. Reiner, S. W. Greenhouse, P. L. Walker, M. L. Simoons, Y. C. Draoui, R. M. Califf, E. J. Topol, et al. Extended Mortality Benefit of Early Postinfarction Reperfusion Circulation, April 28, 1998; 97(16): 1549 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Survival Advantage with t-PA Sustained Over One Year Journal Watch Cardiology, November 1, 1996; 1996(1101): 24 - 24. [Full Text]
|
|
|
|
 |
|
 SURVIVAL ADVANTAGE WITH T-PA SUSTAINED OVER ONE YEAR Journal Watch (General), October 4, 1996; 1996(1004): 4 - 4. [Full Text]
|
|
|
|
|
|
R. Roberts La Difference: Long-term Benefit of One Thrombolytic Over Another Circulation, September 15, 1996; 94(6): 1203 - 1205. [Full Text]
|
|